Montana Healthcare Programs
Physician-Administered Drug Coverage Criteria

SUBLOCADE® (buprenorphine extended-release)

I. Medication Description
Sublocade® contains buprenorphine, a partial opioid agonist, and is indicated for:
- Treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product, followed by dose adjustment for a minimum of seven days

II. Position Statement
In conjunction with established clinical criteria requirements, providers must follow the Addictive and Mental Disorders Division (AMDD) policy requirements. Providers can find the complete policy within the AMDD Medicaid Services Provider Manual posted at the following link: https://dphhs.mt.gov/amdd/

Note: The prescribing provider must be an enrolled Montana Healthcare Programs provider.

III. Initial Coverage Criteria
Member must meet all the following criteria:
- Member is 18 years of age or older.
- Diagnosis of moderate to severe Opioid Use Disorder (DSM-V criteria)
- Please provide X-DEA number of prescriber.
- Member has been stabilized on a buprenorphine transmucosal dose delivering an equivalent of 8-24mg for a minimum of seven days.
- Provider has evaluated potential drug interactions (concurrent use of strong CYP inhibitors or inducers is not recommended).
- Clinical rationale provided documenting necessity to switch to injectable product.
- Consideration will be made to offer member a naloxone rescue prescription and education.
- Provider attests member’s treatment plan includes all the following and will be documented in member chart:
  - Diagnosis of moderate to severe Opioid Use Disorder (DSM-V Criteria)
  - Member will be referred for counseling assessment and counseling.
  - Proposed monitoring plan includes random urine drug screens (to include drugs of abuse and buprenorphine).
  - Treatment contract has been signed by member and member understands:
    - Concurrent opioids, tramadol or carisoprodol will NOT be covered with buprenorphine-containing products.
    - If member subsequently discontinues the buprenorphine-containing product, all opioids, tramadol formulations and carisoprodol will remain on not-covered status. These medications will require prior authorization for any future prescriptions. Approval may be granted short-term for an acute injury, hospitalization or other appropriate diagnosis only after the case is reviewed with the treating provider and the provider prescribing the buprenorphine-containing product.
  - If member pregnant:
    - Estimated due date must be provided.
- Risk/benefit has been discussed with member.
- Treatment provider attests obstetrician (OB) provider has been contacted to establish post-delivery plan (for treatment of neonatal withdrawal syndrome).
- OB provider name, phone and date contacted must be submitted.

IV. **Renewal Coverage Criteria**
   Member must meet all the following criteria:
   - Member has been adherent to Sublocade®.
   - Provider must attest member is making clinically meaningful progress towards treatment goals.

V. **Quantity Limitations**
   Max 300mg monthly x2 months, followed by a maintenance dose of 100mg monthly.

VI. **Coverage Duration**
   Initial approval duration: 6 months
   Renewal approval duration: 1 year